SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Psychopharmacology
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Garland, E. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Garland, E. J.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Reviews

Reviews : Pharmacotherapy of adolescent attention deficit hyperactivity disorder: challenges, choices and caveats

E. Jane Garland

University of British Columbia and British Columbia's Children's Hospital, Vancouver BC, Canada

A recent increase in stimulant treatment of adolescents with attention deficit hyperactivity disorder (ADHD) has been documented. Challenges in treating adolescent ADHD with methylphenidate or dextroamphetamine include compliance with frequent dosing, abuse potential and wear-off or rebound effects. Co-morbid anxiety, occurring in at least 30 percent of ADHD youths, is associated with lower rate of response to stimulants. The effective alternatives, tricyclic antidepressants or pemoline, are each associated with rare but serious toxicity. Bupropion has recently proven effective in controlled trials. Other noradrenergic or dopamine-enhancing agents such as venlafaxine and nicotine show some benefit in open trials. The need for more options in pharmacotherapy of ADHD is evidenced by rapid adoption in clinical practice of alternative and adjunctive medication despite lack of controlled research on efficacy and safety.

The indications for long-term stimulant treatment of ADHD present some controversy, and highlight a need for more research on safety and efficacy through the lifespan. Thresholds for diagnosis are much lower with DSM than with ICD, and thresholds for treatment are contentious, given the performance-enhancing effects of stimulants in normal students. The endpoint for treatment is unclear, as stimulants are also effective in adult ADHD. Based on short- and intermediate-term studies to date, stimulant medication is clearly more efficacious than cognitive and behavioral strategies for the symptoms of ADHD. Longer term research is needed to determine whether sustained stimulant therapy will reduce the adverse emotional, behavioral and academic consequences of inattention and impulsivity in adolescents and adults.

Key Words: adolescence • amphetamines • antidepressive agents • attention deficit disorder with hyperactivity; methylphenidate • pemoline

Journal of Psychopharmacology, Vol. 12, No. 4, 385-395 (1998)
DOI: 10.1177/026988119801200410


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
Neurorehabil Neural RepairHome page
S. Jonsdottir, A. Bouma, J. A. Sergeant, and E. J.A. Scherder
Effects of Transcutaneous Electrical Nerve Stimulation (TENS) on Cognition, Behavior, and the Rest-Activity Rhythm in Children with Attention Deficit Hyperactivity Disorder, Combined Type
Neurorehabil Neural Repair, December 1, 2004; 18(4): 212 - 221.
[Abstract] [PDF]


Home page
J. Neurosci.Home page
R. Kuczenski and D. S. Segal
Exposure of Adolescent Rats to Oral Methylphenidate: Preferential Effects on Extracellular Norepinephrine and Absence of Sensitization and Cross-Sensitization to Methamphetamine
J. Neurosci., August 15, 2002; 22(16): 7264 - 7271.
[Abstract] [Full Text] [PDF]


Home page
J PsychopharmacolHome page
E. J. Sproson, J. Chantrey, C. Hollis, C. A. Marsden, and K. C. F. Fone
Effect of repeated methylphenidate administration on presynaptic dopamine and behaviour in young adult rats
J Psychopharmacol, March 1, 2001; 15(2): 67 - 75.
[Abstract] [PDF]


Home page
J Atten DisordHome page
D. E. Faries, I. Yalcin, D. Harder, and J. H. Heiligenstein
Validation of the ADHD Rating Scale as a clirlician administered and scored instrument
J Atten Disord, January 1, 2001; 5(2): 107 - 115.
[Abstract] [PDF]



Advertisement